Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

6 clinical studies listed.

Filters:

Shingles

Tundra lists 6 Shingles clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ACTIVE NOT RECRUITING

NCT07311148

A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 40 Years and Older

This phase 2 study in China will evaluate the immunogenicity and safety of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.

Gender: All

Ages: 40 Years - Any

Updated: 2025-12-30

1 state

Herpes Zoster (HZ)
Shingles
VZV
+1
RECRUITING

NCT06569823

Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over

This is a randomized, active-controlled, observer-blinded, dose-escalation multi-center trial of 2 doses of an investigational HZ vaccine (Z-1018) in approximately 764 healthy adults.

Gender: All

Ages: 50 Years - Any

Updated: 2025-11-06

3 states

Shingles
Herpes Zoster
Vaccine-Preventable Diseases
ACTIVE NOT RECRUITING

NCT05304351

Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older

The purpose of this study is to assess the safety and immunogenicity of amezosvatein (CRV-101), an investigational vaccine compared to Shingrix® for the prevention of herpes zoster in adults aged 50 years and older

Gender: All

Ages: 50 Years - Any

Updated: 2025-09-30

10 states

Herpes Zoster
Shingles
ACTIVE NOT RECRUITING

NCT06581575

A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.

Gender: All

Ages: 50 Years - Any

Updated: 2025-03-19

7 states

Herpes Zoster (HZ)
Infectious Diseases
Shingles
RECRUITING

NCT05596526

Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients

The purpose of this study is to provide evidence as to whether RZV is immunogenic with an acceptable safety profile in Multiple Sclerosis patients on anti-CD20 treatment.

Gender: All

Ages: 18 Years - 60 Years

Updated: 2024-04-10

Shingles
Zoster
RECRUITING

NCT05554068

Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.

Gender: All

Updated: 2023-03-08

1 state

Shingles